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Objectives The aim of this study was to evaluate the relative impact of spontaneously occurring and periprocedural myocar-
dial infarction (MI) on survival after percutaneous coronary intervention (PCI).
Background The clinical significance of periprocedural MI after PCI remains uncertain.
Methods Outcomes during a 1-year follow-up were evaluated among 7,773 patients enrolled in the ACUITY (Acute Cathe-
terization and Urgent Intervention Triage Strategy) trial with a non–ST-segment elevation acute coronary syn-
drome in whom PCI was performed.
Results Periprocedural MI developed in 466 patients (6.0%), and spontaneous MI unrelated to PCI subsequently devel-
oped in 200 patients (2.6%). Patients developing spontaneous and periprocedural MI compared with those pa-
tients without MI had significantly greater unadjusted rates of mortality at 30 days (5.0% vs. 3.2% vs. 0.8%, re-
spectively, p  0.0001) and at 1 year (16.0% vs. 6.0% vs. 2.6%, respectively, p  0.0001). In a time-updated
multivariable analysis, after adjusting for differences in baseline and procedural characteristics between the
groups, we found that spontaneous MI was a powerful independent predictor of subsequent mortality (hazard
ratio: 7.49, 95% confidence interval: 4.95 to 11.33, p  0.0001), whereas periprocedural MI was not a signifi-
cant predictor of mortality (hazard ratio: 1.30, 95% confidence interval: 0.85 to 1.98, p  0.22).
Conclusions Among patients with acute coronary syndrome undergoing PCI, the spontaneous development of an MI unre-
lated to PCI is a powerful predictor of subsequent mortality. In contrast, periprocedural MI is a marker of baseline
risk, atherosclerosis burden, and procedural complexity but in most cases does not have independent prognostic sig-
nificance. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes [ACS]; NCT00093158) (J Am Coll
Cardiol 2009;54:477–86) © 2009 by the American College of Cardiology Foundation
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Prognostic Significance of MI July 28, 2009:477–86Myonecrosis is a common se-
quela of percutaneous coronary
intervention (PCI) (1). However,
the incidence (3.6% to 48.8%)
and magnitude of myocardial
damage after PCI is highly vari-
able, depending on the patient’s
clinical, angiographic, and proce-
dural characteristics; adjunctive
pharmacotherapy; and the bi-
omarker and thresholds applied
to detect its presence (1). Early
studies, in which the investiga-
ors predominantly used creatine phosphokinase myocardial
and (CK-MB) fraction as a measure of myocardial injury,
ndicated that periprocedural myocardial infarction (MI),
efined as either a peak post-procedural CK-MB of 5 
he upper limits of normal (ULN) (2,3) or 8  ULN or
ssociated with the development of new pathologic Q waves
4), is associated with an independent risk of in-hospital
eath (2–5) and reduced long-term survival (2,4–7).
Although the clinical significance of PCI-related myone-
rosis remains controversial, particularly when it is relatively
inor and occurs in the absence of angiographic complica-
ions or clinical evidence of ischemia (8,9), periprocedural
I (which is most commonly due to distal embolization,
ide-branch occlusion, coronary dissection, and altered col-
ateral flow) (10,11) and spontaneous MI unrelated to PCI
typically due to atherosclerotic plaque rupture) (12,13) are
ften equated as outcome measures in clinical trials (14,15).
hether this practice is valid has not been examined and is
onfounded by the variable definitions used for periproce-
ural MI, making comparisons between studies difficult.
Although large MIs occurring after PCI are undoubtedly
rognostically important, small degrees of myonecrosis
e.g., troponin elevations greater than the ULN) have not
een correlated with early or late mortality (16). Even when
reater thresholds of myonecrosis are used to define peripro-
edural MI, there is a paucity of data regarding the relative
rognostic significance of MI occurring after a PCI proce-
ure compared with a spontaneously occurring event. We
herefore sought to compare the prognostic impact of
eriprocedural and spontaneously occurring MI on subse-
uent mortality among moderate- and high-risk patients
uke.edu/research/coi.jsp. Dr. White has received research grants from Sanofi-
ventis, Eli Lilly, The Medicines Company, National Institutes of Health, Pfizer,
oche, Johnson & Johnson, Schering-Plough, Merck Sharpe & Dohme, Astra-
eneca, GlaxoSmithKline, and Daiichi Sankyo Pharma Development, and
onsulting fees from GlaxoSmithKline and Sanofi-Aventis. Dr. Pocock has
eceived consulting fees from The Medicines Company. Dr. Cox is a member of
he Speakers’ Bureau of The Medicines Company. Dr. Mehran has been a
onsultant with Abbott and has received speaking honoraria from The Medicines
ompany, Lily/Daiichi Sankyo, Medtronic Vascular, Boston Scientific, Cordis
orp., and Sanofi-Aventis. Dr. Stone has received research grants from The
edicines Company, Boston Scientific, and Abbott Vascular.
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and Acronyms
ACS  acute coronary
syndrome
CK-MB  creatine
phosphokinase MB fraction
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ULN  upper limit of
normalw
Manuscript received December 30, 2008; revised manuscript received February 19,
009, accepted March 24, 2009.ith acute coronary syndrome (ACS) undergoing PCI from
he large, multicenter, prospective ACUITY (Acute Cath-
terization and Urgent Intervention Triage Strategy) trial
17–19).
ethods
atients. The design of the ACUITY trial has been de-
cribed previously (17,18). In brief, to enroll a study popu-
ation with moderate- and high-risk non–ST-segment ele-
ation ACS, patients age 18 years or older with symptoms
f myocardial ischemia lasting for 10 min or longer within
he preceding 24 h were deemed to be eligible for enrolment
f one or more of the following criteria were met: new
T-segment depression or transient elevation of 1 mm or
ore; increased levels of troponin I, T, or CK-MB; known
oronary artery disease; or the presence of all 4 other
nstable angina risk criteria as defined by the Thrombolysis
n Myocardial Infarction (TIMI) study group (20).
Major exclusion criteria included acute ST-segment ele-
ation MI or shock; bleeding diathesis or major bleeding
pisode within 2 weeks; thrombocytopenia; calculated cre-
tinine clearance 30 ml/min; recent administration of
bciximab, warfarin, fondaparinux, fibrinolytic agents, biva-
irudin, or 2 or more doses of low molecular mass heparin;
nd allergy to study drugs or iodinated contrast that could
ot be adequately pre-medicated. The study was approved
y the institutional review board or ethics committee at each
articipating center, and all patients gave written, informed
onsent.
rocedures. Patients were randomly assigned in open-label
ashion to heparin (unfractionated or enoxaparin) plus a
lycoprotein IIb/IIIa inhibitor, bivalirudin plus a glyco-
rotein IIb/IIIa inhibitor, or bivalirudin monotherapy (al-
owing for the use of provisional glycoprotein IIb/IIIa
nhibitors). Details of the anticoagulant regimens have been
escribed previously (18,19). Angiography was performed
er protocol within 72 h after randomization, after which the
ecision was declared and recorded for primary treatment
ither with PCI, coronary artery bypass grafting, or medical
anagement. All patients undergoing PCI received dual an-
iplatelet therapy for a recommended duration of 1 year.
Of the 13,819 patients enrolled into the ACUITY trial,
,789 (56%) were managed with an invasive strategy that
ncluded PCI. The baseline clinical and angiographic char-
cteristics and outcomes of the PCI population have been
reviously reported (18,19). We determined CK-MB mea-
urements every 8 h within the first 24 h after PCI.
ystematic analysis of CK-MB curves was performed for all
atients after PCI to detect unreported MI. The definitions
f MI used in the trial are listed in Table 1. The Clinical
vents Committee reviewed original source documentation
rom all patients with suspected MI to ensure consistency of
I determination.
With regards to timing of the event, periprocedural MIas defined as an event occurring on the day of or the day
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July 28, 2009:477–86 Prognostic Significance of MIfter the procedure, whereas a spontaneous MI was defined
s one occurring after this time period. Periprocedural MIs
ere recorded, whether related to the index procedure
erformed at the time of enrollment into the trial or a
ubsequent PCI during follow-up. To minimize the impact
f crossover, patients were excluded if they exhibited both
ypes of MI during the study period, that is, periprocedural
I followed by a subsequent spontaneous MI (n  13, 5 of
hom died during 1-year follow-up) or spontaneous MI
ollowed by a MI related to PCI performed after the index
evascularization (n  3, no deaths). Thus, the study cohort
or the current analysis consisted of 7,773 (99.8%) of the
,789 patients undergoing an index PCI.
tatistical analysis. Categorical variables were compared
ith the chi-square test or Fisher exact test. Continuous
ariables were compared with the nonparametric Wilcoxon
ank-sum test. Comparisons among groups for the 30-day
nd points were made with the use of the normal approxi-
ation test for population proportions. A 2-sided   0.05
as used for all superiority testing. One-year follow-up
nalysis on mortality was performed with the use of time-
o-event data (for which patients were censored at the time
f withdrawal from the study or at last follow-up), are
isplayed with the use of Kaplan-Meier methodology, and
ere compared with the log-rank test. The independent
mpact of the occurrence of MI by type was evaluated by the
se of a time-updated Cox proportional hazards regression
odel. Covariates were selected by the use of a forward
tepwise procedure from a large number of candidate
ariables with p  0.20 as the criterion for entry into the
odel. Adjusted hazard ratios of the risk for mortality with
efinition of MITable 1 Definition of MI
Periprocedural MI Patients presenting with or without NSTEMI in whom
elevated CK-MB (or CPK) levels are decreasing
from a previous peak or are normal: any CK-MB
(or CPK in the absence of CK-MB measurement)
3  ULN within 24 h after PCI that is also
increased at least 50% over the most recent pre-
PCI levels or the development of new, significant
(0.04 s) Q waves in 2 or more contiguous
electrocardiographic leads with CK-MB (or CPK)
greater than ULN.
Patients presenting with NSTEMI in whom the peak
CK-MB (or CPK) has not yet been reached before
PCI: recurrent chest pain lasting 30 min and/or
new electrocardiographic changes consistent with
a second MI and either the next CK-MB (or CPK)
level measured 8 to 12 h after the event is
increased by at least 50% greater than the
previous level or the development of new,
significant (0.04 s) Q waves in 2 or more
contiguous electrocardiographic leads.
Spontaneous MI Any elevation of troponin or CPK-MB (or CPK)
greater than the ULN.
K-MB  creatine kinase-myocardial band; CPK  creatine phosphokinase; MI  myocardial
nfarction; NSTEMI  non–ST-segment myocardial infarction; PCI  percutaneous coronary inter-
ention; ULN  upper limit of normal.5% confidence intervals are presented. All statistical anal- dses were performed with SAS version 8.2 (SAS Institute,
ary, North Carolina).
esults
requency and timing of MI. Of the 7,773 patients with
on–ST-segment elevation ACS undergoing PCI, 466
atients (6.0%) and 200 patients (2.6%) developed a
eriprocedural MI and spontaneous MI, respectively, within
he 1-year follow-up duration of the study. Of patients with
eriprocedural MI, 366 (78.5%) occurred within the index-
CI procedure, and 100 (21.5%) occurred after subsequent
CI procedures at a median time of 68 (interquartile range
to 214) days after randomization. Thus, 410 (88.0%) of all
he periprocedural MIs occurred within 30 days of random-
zation. Eighty-seven (18.7%) of all the periprocedural MIs
ccurred after index-hospital discharge. The spontaneously
ccurring MI events occurred at a median time of 107.5
interquartile range 20 to 247) days after randomization; 64
32.0%) of all the spontaneous MIs occurred within 30 days
f randomization. New Q waves, as determined by the
linical events committee, developed in 81 (17.4%) of
eriprocedural MIs and in 37 (18.5%) of spontaneous MIs
p  0.73).
Stent thrombosis (ST) was classified as either definite or
robable. Definite ST was defined as angiographic throm-
us or subacute closure within the stented vessel at the time
f clinically driven angiography for ischemia. Probable ST
as defined as any death not attributed to a noncardiac
ause or any Q-wave MI in the absence of documented
ngiographic stent patency. At 1 year, definite and probable
ates of ST in the overall study population were 1.2% and
.7%, respectively. The respective rates in patients with
eriprocedural MI were 58 (12.4%) and 10 (2.1%), and for
hose with spontaneous MI were 21 (10.1%) and 15 (7.5%).
aseline characteristics. The clinical characteristics of the
groups are summarized in Table 2. In general, patients
ith either periprocedural or spontaneous MI compared
ith those in whom MI did not develop were more likely to
ave had a past medical history of MI, previous revascular-
zation, impaired renal function and a greater TIMI risk
core. There were no differences in age, sex distribution,
istory of hyperlipidemia or smoking, and the frequency of
on–ST-segment elevation MI at the time of enrollment
etween the 3 groups of patients. There were no significant
aseline differences between the 2 MI groups, except for a
reater prevalence of diabetes mellitus in patients with
pontaneously occurring MI. Treatment with aspirin, beta-
lockers, angiotensin-converting enzyme inhibitors, and
tatins in the first 30 days after discharge was similar among
he 3 groups (Table 2).
ngiographic and procedural characteristics. As shown
n Table 3, compared with patients in whom a MI did not
evelop, patients sustaining a periprocedural MI were more
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Prognostic Significance of MI July 28, 2009:477–86ikely to undergo multilesion and multivessel PCI and
ntervention involving the left main coronary artery, left
ircumflex artery, or a saphenous vein bypass graft. Bypass
raft intervention was also more common in patients in
hom a spontaneous MI developed, although no other
ngiographic or procedural predictors were predictive of
pontaneous MI.
linical outcomes. By univariate analysis, patients with
oth periprocedural MI and spontaneous MI had greater
ates of unplanned revascularization for ischemia, major
leeding, and mortality within 30 days compared with
atients without MI (Fig. 1). Compared with patients
ithout MI, mortality rates at 1 year were significantly
ncreased in patients with both periprocedural MI (6.0% vs.
.6%, p  0.0001) and spontaneous MI (16.0% vs. 2.6%,
 0.0001) (Fig. 2A). The difference in mortality in
atients with spontaneously occurring MI versus periproce-
ural MI was also highly significant (p  0.0001). The
ndings were similar when the analysis was performed
eparately for patients with unstable angina or non–ST-
egment elevation MI as the index diagnosis (Figs. 2B and
C). The rate of mortality in patients with ST compared
ith those without ST was significantly greater for both
ypes of MI (p  0.01) (Fig. 3). Mortality at 1 year in
atients with periprocedural Q-wave MI and spontaneous
-wave MI was 27.0% and 17.3%, p  0.22, respectively.
In the time-updated covariate adjusted multivariate anal-
sis, spontaneously occurring MI was the strongest inde-
endent predictor of subsequent mortality within the fol-
aseline Clinical CharacteristicsTable 2 Baseline Clinical Characteristics
Periprocedural MI
(n  466)
Age (yrs) 64.0 (55, 73)
Female 133/466 (28.5)
Diabetes 123/461 (26.7)
Hypertension 323/464 (69.6)*
Hyperlipidemia 265/457 (58.0)
Current cigarette smoker 145/460 (31.5)
Previous MI 169/451 (37.5)‡
Previous PCI 200/463 (43.2)*
Previous CABG 118/465 (25.4)‡
Baseline CrCl 60 ml/min 112/443 (25.3)‡
Baseline increased CK-MB/troponin 295/442 (66.7)
TIMI risk score
0–2 44/466 (9.4)†
3–4 224/446 (48.1)
5–7 148/466 (31.8)*
Post-discharge to 30 days’ medications
Aspirin 431/444 (97.1)
Clopidogrel 397/444 (89.4)
Angiotensin-converting enzyme inhibitor 288/444 (64.9)
Statins 379/444 (85.4)
alues are median (interquartile range) or n/N (%). The p values are for the comparison of peripr
omparison with patients without MI; ‡p  0.001 for comparison with patients without MI.
CABG  coronary artery bypass grafting; CrCl  creatinine clearance; TIMI  Thrombolysis In Mowing year (hazard ratio: 7.49, 95% confidence interval: A.95 to 11.33, p 0.0001). In contrast, after adjustment for
aseline variables, periprocedural MI as a group was not
ignificantly related to subsequent mortality (hazard ratio: 1.30,
5% confidence interval: 0.85 to 1.98, p  0.22) (Fig. 4).
iscussion
he major findings of the present study among patients
ndergoing PCI for a non–ST-segment elevation ACS
re as follows: 1) periprocedural and spontaneously oc-
urring MIs develop in patients with a greater prevalence
f adverse clinical and angiographic baseline characteris-
ics; 2) periprocedural and spontaneously occurring MIs are
oth associated with greater 30-day morbidity and 1-year
ortality; and 3) after correction for differences in baseline
linical and angiographic characteristics of the groups, the
evelopment of a spontaneous MI, but not a periprocedural
I, independently predicts subsequent mortality within the
ollowing year.
utcomes after spontaneous and procedural MI. The
CUITY trial was designed to be representative of contem-
orary practice in moderate- and high-risk patients with
on–ST-segment elevation ACS; an invasive approach was
outinely used (with 93% of PCI patients stented), and
djunctive anticoagulant therapy included either the admin-
stration of bivalirudin alone or a glycoprotein IIb/IIIa
nhibitor in combination with either unfractionated or low
olecular weight heparin, all of which are recommended
ith Class I level of evidence according to the most recent
Spontaneous MI
(n  200) p Value
PCI Without MI
(n  7,107)
64.0 (53, 73) 0.87 63.0 (54, 71)
57/200 (28.5) 0.99 1,896/7,107 (26.7)
77/200 (38.5)‡ 0.002 1,928/7,064 (27.3)
137/200 (68.5) 0.78 4,603/7,071 (65.1)
119/200 (59.5) 0.72 3,889/6,967 (55.8)
60/197 (30.5) 0.79 2,152/6,968 (30.9)
78/195 (40.0)† 0.54 2,064/6,959 (29.7)
97/197 (49.2)† 0.15 2,681/7,050 (38.0)
55/200 (27.5)‡ 0.57 1,182/7,092 (16.7)
56/190 (29.5)‡ 0.27 1,179/6,698 (17.6)
129/189 (68.3) 0.71 4,292/6,618 (64.9)
18/200 (9.0)* 0.86 1,047/7,107 (14.7)
91/200 (45.5) 0.54 3,380/7,107 (47.6)
71/200 (35.5)† 0.35 1,898/7,107 (26.7)
180/186 (96.8) 0.84 6,735/6,947 (96.9)
166/186 (89.2) 0.95 6,240/6,947 (89.8)
113/186 (60.8) 0.33 4,319/6,947 (62.2)
163/186 (87.6) 0.45 5,912/6,947 (85.1)
al MI versus spontaneous MI: *p  0.05 for comparison with patients without MI; †p  0.01 for
ial Infarction; other abbreviations as in Table 1.ocedurmerican College of Cardiology/American Heart Associa-
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July 28, 2009:477–86 Prognostic Significance of MIion guidelines (21). Although one third of patients in this
rial were also treated with bivalirudin plus a glycoprotein
Ib/IIIa inhibitor (not a currently recommended regimen),
he outcomes in this cohort (including rates of MI, bleed-
ng, and mortality) were comparable with patients receiving
eparin plus a glycoprotein IIb/IIIa inhibitor, thus justifying
ooling the results from the present analysis.
Figure 1 30-Day Rates of Mortality, Unplanned Revascularizati
Results are shown for patients with periprocedural myocardial infarction (MI), spon
ngiographic and Procedural CharacteristicsTable 3 Angiographic and Procedural Characteristics
Periprocedural MI
(n  466)
Baseline ejection fraction (%) 55 (45, 60)
Number of lesions treated
1 241/457 (52.7)‡
2 142/457 (31.1)‡
3 49/457 (10.7)†
Number of vessels treated
1 357/465 (76.8)‡
2 90/465 (19.4)†
3 14/465 (3.0)†
Treated vessel
Left main 13/462 (2.8)*
Left anterior descending 196/462 (42.4)
Right coronary artery 175/462 (37.9)
Left circumflex artery 187/462 (40.5)*
Bypass graft 67/462 (14.5)‡
Stent implanted 431/459 (93.9)
Distal protection 17/459 (3.7)‡
Atherectomy 3/459 (0.7)
Thrombectomy 11/459 (2.4)
Anticoagulant therapy
Heparins and glycoprotein IIb/IIIa 140/466 (30.0)
Bivalirudin and glycoprotein IIb/IIIa 162/466 (34.8)
Bivalirudin alone 164/466 (35.2)
alues are median (interquartile range) or n/N (%). The p values are for the comparison of periproc
I; †p  0.01 for comparison with patients without MI; and ‡p  0.001 for comparison with patAmong patients with moderate- and high-risk non–ST-
egment elevation ACS in ACUITY who did not experi-
nce either a periprocedural or subsequent MI within the
ear after undergoing PCI, the 30-day and 1-year rates of
ortality were relatively low (0.8% and 2.6%, respectively).
owever, the unadjusted rates of mortality at both 30 days
nd 1 year were significantly greater among the 6.0% and
nd Major Bleeding Unrelated to CABG
us MI, and no MI. CABG  coronary artery bypass grafting.
Spontaneous MI
(n  200) p Value
PCI Without MI
(n  7,107)
55 (40, 60) 0.54 55 (50, 62)
111/192 (57.8)* 0.24 4,655/7,010 (66.4)
55/192 (28.6) 0.54 1,668/7,010 (23.8)
20/192 (10.4) 0.91 518/7,010 (7.4)
167/200 (83.5) 0.05 5,968/7,104 (84.0)
30/200 (15.0) 0.18 1,027/7,104 (14.5)
3/200 (1.5) 0.26 101/7,104 (1.4)
2/198 (1.0) 0.15 108/7,061 (1.5)
88/198 (44.4) 0.63 3,031/7,061 (42.9)
71/198 (35.9) 0.62 2,598/7,061 (36.8)
73/198 (36.9) 0.38 2,433/7,061 (34.5)
31/198 (15.7)‡ 0.70 458/7,065 (6.5)
181/196 (92.3) 0.46 6,535/7,046 (92.7)
4/196 (2.0) 0.27 90/7,046 (1.3)
1/196 (0.5) 0.83 44/7,046 (0.6)
4/196 (2.0) 0.78 113/7,046 (1.6)
58/200 (29.0) — 2,360/7,107 (33.2)
68/200 (34.0) — 2,372/7,107 (33.4)
74/200 (37.0) — 2,375/7,107 (33.4)
yocardial infarction (MI) versus spontaneous MI: *p 0.05 for comparison with patients without
thout MI.on, a
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Prognostic Significance of MI July 28, 2009:477–86.6% of the study cohort in whom a procedure-related or
pontaneously occurring MI did develop. At least part of
Figure 2 Time-to-Event Curves for 1-Year Mortality
(A) Kaplan-Meier estimates of 1-year death among all patients. (B) Kaplan-Meier estimate
diagnosis of non–ST-segment elevation myocardial infarction (MI). (C) Kaplan-Meier estimahis risk may be attributed to a greater underlying burden of atherosclerosis in patients in whom an MI developed, as
ndicated by the greater prevalence of classic risk factors for
year death among percutaneous coronary intervention (PCI) patients admitted with a
1-year death among PCI patients admitted with a diagnosis of unstable angina.s of 1-
tes oftherosclerosis, history of previous MI and revasculariza-
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July 28, 2009:477–86 Prognostic Significance of MIion, and greater renal impairment and TIMI risk scores
mong these patients.
The PCI procedure in patients in whom a periprocedural
I developed, in particular, was also more complex; it more
requently involved multilesion and multivessel, left main,
nd bypass graft intervention. The frequency of definite ST
t 1 year was similar in both types of MI (p 0.48), and the
ate of mortality in patients with ST was markedly greater
ompared with those without for both types of MI (p 
.01) (Fig. 3). However, spontaneous MI even without
T was associated with high rates of mortality at 1 year
12.0%), but the rate of mortality in patients with
eriprocedural MI without ST (4.1%) approximated that
f patients without MI.
A time-updated multivariable regression analysis was per-
ormed to adjust for the differences in baseline clinical and
rocedural characteristics and the timing of MI among patients
ith periprocedural MI, spontaneous MI, and no MI. In this
odel, the spontaneous development of an MI (unrelated to
CI) was the strongest independent predictor of subsequent
ortality within the 1-year follow-up period (hazard ratio:
.5), whereas periprocedural MI was not an independent
redictor of death. Age, diabetes mellitus, previous MI, and
enal failure, as well as markers for the severity of the ACS such
s preprocedural biomarker elevation and ST-segment shift,
ere additional independent predictors of long-term mortality.
hese findings demonstrate that the development of a spon-
aneously occurring MI is of significantly greater prognostic
Figure 3 Time-to-Event Curves for 1-Year Mortality in Patients
Mortality in patients with stent thrombosis was greater (p  0.01) compared withmportance than a periprocedural MI. irognostic significance of periprocedural MI. The lack
f independent association between PCI-related MI and
ortality in the present analysis is contrary to the findings of
revious studies (2,4–7), which may in part be attributable
o the different thresholds and definitions for MI used.
eriprocedural MI in the present trial required a CK-MB
levation of 3  ULN, which is significantly below the
hreshold levels of CK-MB 5 or 8  ULN required for
rognostic significance in the 2 largest previous studies
2,4). Moreover, we have recently demonstrated that this
agnitude of periprocedural CK-MB elevation is infrequent in
atients with normal pre-procedural cardiac biomarkers and
s mostly observed in patients with increased levels of
roponin T (0.5 ng/ml) (22).
We have also demonstrated in the previous study that
mong patients with normal pre-procedural CK-MB (ap-
roximately one-third of patients in the current study), a
ost-procedure increase in CK-MB greater than normal
oes not independently predict mortality when the pre-
rocedural cardiac troponin T levels are included in the
ultivariate models (22). Most previous studies correlating
eriprocedural MI to subsequent mortality have not rou-
inely assessed or adjusted the results for the baseline
roponin level (2,4–7), representing an important unmea-
ured confounder in these studies.
Moreover, in the present and previous studies (1,22),
eriprocedural myonecrosis has been shown to occur more
requently in patients with multiple cardiac risk factors,
and Without Stent Thrombosis
without, for both types of myocardial infarction (MI).With
thosencluding advanced age, diabetes, and hypertension; in
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Prognostic Significance of MI July 28, 2009:477–86atients with ACS and thrombus; and in those undergoing
ultilesion and multivessel intervention. The results of
ntravascular ultrasound studies have shown patients devel-
ping periprocedural myonecrosis after PCI have more
xtensive atherosclerosis (23). Thus, periprocedural MI is a
arker of clinical syndrome acuity, atherosclerotic plaque
urden, and procedural complexity, and although increases
n periprocedural cardiac enzyme do represent myonecrosis
24,25), in most cases the level of myocardial damage is
elow the threshold to significantly increase short-term or
ate mortality.
rognostic significance of spontaneous MI. Our study
uantifies the risk associated with a spontaneously occurring
I occurring after an initial invasive strategy for patients
ith non–ST-segment elevation ACS. Indeed, after adjust-
ng for differences in baseline and procedural characteristics,
pontaneous MI was the strongest independent predictor of
ubsequent mortality. This observation is consistent with
tudies conducted among patients with ST-segment eleva-
ion MI treated with primary PCI. Kernis et al. (26)
eported data from the PAMI (Primary Angioplasty in MI)
rial and demonstrated that recurrent MI in the first month
fter primary PCI occurred in 2.1% of patients and was
ssociated with a 7-fold increased risk of death at 6 months.
imilar data were reported by de Luca et al. (27). It is
oteworthy that, despite the difference in the patient pop-
Figure 4 Independent Predictors of 1-Year Mortality
Time-updated baseline covariate adjusted multivariate model in which periprocedu
larization were entered as time-dependent covariates. Additional variables included
idemia, hypertension, current smoking, coronary artery disease, previous PCI or CA
treatment assignment in the trial. CK-MB  creatine kinase, myocardial band; CrC
unfractionated heparin; other abbreviations as in Figure 1.lations and MI definitions and greater use of stents and llycoprotein IIb/IIIa inhibitors in the present study, the
ncidence of spontaneous MI and the magnitude of impact
n mortality were comparable to the previous studies.
revious studies. Akkerhuis et al. (28) have previously
ompared the impact of periprocedural CK-MB elevation
fter PCI with spontaneous, non–PCI-related, CK-MB
levation on 6-month mortality in patients with non–ST-
egment elevation ACS. There was a direct correlation
etween CK-MB levels and mortality in both groups. As
n the present study, however, the rate of mortality was
ignificantly greater in patients with spontaneous MI
ompared with those with periprocedural myonecrosis.
he authors concluded that the adverse prognostic im-
lications of periprocedural myocardial necrosis should
e considered similar to the adverse consequences of
pontaneous myocardial necrosis. Several important dif-
erences between our study and that by Akkerhuis et al.
28) may account for the discordant conclusions. First,
he previous study was conducted in the balloon angio-
lasty era and, hence, not representative of contemporary
ractice. Second, Akkerhuis et al. (28) did not adjust for
onfounding clinical variables to determine whether the
bserved relationship was independent of baseline risk.
inally, the previous study consisted of a heterogeneous
roup of patients from 5 different clinical trial databases.
tudy limitations. Although the ACUITY trial was a
spontaneously occurring MI, non-CABG major bleeding, and unplanned revascu-
model that were not independent predictors included weight, history of hyperlip-
ienopyridine therapy pre-intervention, heparin use pre-randomization, and
atinine clearance; ECG  electrocardiogram; MI  myocardial infarction; UFH ral MI,
in the
BG, th
l  crearge, multicenter, prospective trial incorporating currently
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July 28, 2009:477–86 Prognostic Significance of MIecommended class I guideline therapies for ACS, the
resent analysis was retrospective and post hoc and, hence,
ubject to bias. Core laboratory angiographic analysis was
ot available in all patients. There are several limitations
ith regards to the definition of MI used in the present
nalysis. First, creatine phosphokinase and CK-MB were
sed to define periprocedural MI (based on the accepted
ractice at the time the study was designed), whereas
K-MB and troponins were used for spontaneous MI
reflecting clinical practice). Second, core laboratory analysis
f biomarkers was not performed, as recommended in the
ecently published “universal definition” of MI (28). Third,
he determination of PCI-related MI can be difficult among
atients presenting with a non–ST-segment elevation MI in
hom the pre-procedural cardiac markers have not returned
o baseline. Fourth, a dichotomous cut-off of time after PCI
as used to define periprocedural versus spontaneous MI,
hich may have resulted in some late periprocedural events
rossing over into the spontaneous category.
The impact of these limitations was minimized by the use
f strict definitions formulated a priori to identify the 2
ypes of MI, and each event was adjudicated by an inde-
endent clinical events committee after review of original
ource documents. Importantly, the results of this study thus
pply to patients with unstable angina and non–ST-
egment elevation MI and should not be generalized to
ther clinical scenarios, such as PCI in patients with stable
oronary artery disease or evolving ST-segment elevation
I. Data regarding biomarker levels after the MI were not
outinely collected and, therefore, the relationship between
he magnitude of myocardial injury and outcomes cannot be
etermined, although Q-wave MI developed in a similar
ercentage of patients with both periprocedural and spon-
aneous MI. This is relevant because spontaneous MI were
linical events whereas screening for periprocedural MI was
erformed systematically using biomarker measurements.
Thus, spontaneous MI that occurred without symptoms
r had an atypical presentation may not have been included
n the analysis. Even though the threshold for detection of
pontaneous MI (any troponin  normal) was lower than
hat for periprocedural MI (CK-MB 3  ULN), it is
ossible that spontaneous MI were larger than periproce-
ural MI. However, the present study demonstrates that
eriprocedural MI, as a class, are not of significant inde-
endent prognostic importance after PCI in ACS using
ontemporary management strategies. In contrast, sponta-
eous MI, as a class, are a powerful predictor of subsequent
ortality. Among such patients, it is intuitive that large MI
ould impact mortality greater than small MI, though the
resent study is unable to evaluate this possibility.
onclusions
or the approximately 91% of patients with non–ST-
egment elevation ACS undergoing PCI who do not sustain
periprocedural or spontaneous MI, the 1-year prognosis isavorable. Periprocedural MI, defined as a post-procedure
K-MB 3  ULN, occurs in 6% of patients and
orrelates with baseline patient comorbidities, underlying
therosclerosis, and procedural complexity. However, after
ccounting for these covariates, periprocedural MI is not a
ignificant predictor of subsequent mortality in most pa-
ients. In contrast, the spontaneous occurrence of MI
nrelated to PCI in patients with ACS is a relatively
nfrequent event, developing in only 2.6% of patients within
he first year, but when it occurs is a powerful independent
redictor of subsequent mortality. Our findings support the
ecommendation of the European Society of Cardiology/
merican College of Cardiology/American Heart Associa-
ion/World Heart Federation global task force that sponta-
eous and periprocedural MI should be classified separately
29) and considered discretely for clinical decision making.
urthermore, these findings have important implications for
he design of future randomized trials, demonstrating that
eriprocedural and spontaneous MI should not necessarily
e considered equivalent as clinical event end points (30).
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